Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab for sepsis or septic shock in ICU patients
MOH_2018-08-12_003548Phase 3Not yet recruiting
- Sponsor
- ד"ר רוזמן זיו
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sepsis and septic shock comparing Usual care + Praluent with Usual care + placebo (2 arms). Primary endpoint: Safety of alirocumab in sepsis. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
alirocumab
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on MOH_2018-08-12_003548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-08-12_003548.